Pfizer's big deal in limbo as it has yet to shed consumer-health unit
New York
PFIZER Inc's move to offload its consumer-health division could bring in billions of dollars and help the drugmaker streamline operations. Yet the company-changing deal investors have been hoping for may be still to come.
The US drug giant, which abandoned a plan to split in two last year, has tried - and failed - to orchestrate hundred-billion-dollar-plus mergers that would have allowed it to move its address overseas to secure a lower tax rate. Now, with tax reform being debated in Congress, Pfizer could consider another large deal to bolster its development pipeline.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
US bill to restrict WuXi AppTec, Chinese biotechs revised to give more time to cut ties
New weight-loss, diabetes drugs reach one in eight Americans
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife says private placement is to address urgent cash needs
Cordlife substantial shareholders lay out separate plans to address issues after AGM
Disney, Warner Bros Discovery launch US streaming bundle